Test Price
7,000 AED✅ Home Collection Available
Oncomine Breast cfTNA Assay (NGS) in UAE | 7000 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
The Oncomine Breast cfTNA Assay is a non‑invasive plasma‑based NGS test analyzing circulating tumor nucleic acids for breast cancer genomic alterations. It delivers actionable insights for targeted therapy and resistance monitoring with the following core metrics:
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM–11 PM).
- Turnaround Time: 14–21 calendar days.
- Clinical Guidance: Telephonic post‑test consultation with a DHA‑licensed clinician.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Oncomine Breast cfTNA Assay is a non‑invasive plasma‑based NGS test that analyzes circulating tumor nucleic acids to detect breast cancer‑specific genomic alterations. It delivers actionable insights for targeted therapy and resistance monitoring within 2–3 weeks. This advanced test provides a safe alternative to traditional tissue biopsies, enabling longitudinal monitoring of clonal evolution and treatment response.
| Feature | Our Test: Oncomine Breast cfTNA Assay | Closest Alternative: Tissue NGS Panel |
|---|---|---|
| Methodology | NGS (Illumina®) – Cell‑free total nucleic acid (cfTNA) | NGS – Formalin‑fixed paraffin‑embedded (FFPE) tissue |
| Sample Type | 10 mL peripheral blood (liquid biopsy) | Invasive tissue biopsy |
| Turnaround Time | 14–21 days | 21–28 days (often delayed by tissue processing) |
| Sensitivity | ≥99.9% for key hot‑spot mutations | 95–98% depending on tumour content |
| Clonal Monitoring | Yes – sequential monitoring possible | Limited – new biopsy required |
| DHA Compliance | Licensed Facility #1143 | Subject to tissue lab accreditation |
Physician Insight & Safety Protocols
"As a DHA‑licensed Specialist Diagnostic Radiology, I reassure patients that the Oncomine Breast cfTNA Assay is a powerful, non‑invasive tool to guide personalized breast cancer care. However, a positive finding must always be correlated with clinical imaging and histopathology; a negative result does not exclude the presence of cancer. Please continue all prescribed treatments and consult your oncologist before making any changes."
— Mr. Prabhakar Reddy Kalathoor, DHA Registration ID: 61713011
Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor. This test is a complementary tool and not a substitute for ongoing oncological follow‑up and imaging surveillance.
Exclusion Criteria & Emergency Red Flags
- Pregnancy: Test is not validated for pregnant individuals; discuss with your doctor before testing.
- Major surgery (planned or recent): Physiological stress may alter circulating nucleic acids; postpone test for 4–6 weeks post‑surgery.
- Active acute infection/inflammation: Can cause elevated background cfDNA, potentially masking tumour‑specific signals.
- ER red flags: Seek immediate medical attention if you experience new breast lump, persistent pain, skin changes, or unexplained weight loss — do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the Oncomine Breast cfTNA Assay and how reliable is it?
The Oncomine Breast cfTNA Assay is a liquid biopsy that detects breast cancer genomic alterations with 99.9% diagnostic sensitivity using NGS. It is DHA‑licensed and performed using a simple blood draw, providing a safe and convenient alternative to invasive tissue biopsy.
2. Do I need a doctor’s prescription and can I book home collection?
Yes, a valid doctor’s prescription is mandatory. We offer integrated tele‑consultation to obtain one if needed. Home collection is available 8 AM–11 PM daily via our VIP Mobile Phlebotomy service with temperature‑controlled cold‑chain logistics.
3. How long do results take and who explains them?
Results are delivered in 14–21 calendar days, followed by a complimentary post‑test phone consultation with a DHA‑licensed clinician who will explain the report and guide you on next steps.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Privacy Guarantee
This service operates under Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring clinical testing safety and informed patient consent. All personal health data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic information is never shared without explicit written consent. Laboratory accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | Oncomine Breast cfTNA Assay (NGS) |
| Price (AED) | 7,000 |
| Turnaround Time | 14–21 calendar days |
| Sample Type / Matrix | 10 mL peripheral whole blood (cfTNA) – VIP Mobile Phlebotomy & Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (Illumina®) – cell‑free total nucleic acid analysis |
| ICD-10-CM Code | C50.919 (Malignant neoplasm of unspecified site of unspecified female breast) |
| LOINC Code | 88040-1 |
| DHA Facility License & Laboratory Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians